In vivo evidence for chylomicrons as mediators of postprandial inflammation

Atherosclerosis

Volumn 243, Issue 2, 2015, Pages 540-545

  de Vries, Marijke A ^a   Klop, Boudewijn ^a   Alipour, Arash ^a   van de Geijn, Gert Jan M ^b   Prinzen, Lenneke ^b   Liem, Anho H ^c   Valdivielso, Pedro ^d   Rioja Villodres, José ^d   Ramírez Bollero, José ^d   Castro Cabezas, Manuel ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Clinical Chemistry ^*  (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

^d UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Apolipoprotein B48; Apolipoproteins; Atherosclerosis; Leukocyte activation; Monocytes; Neutrophils; Postprandial lipemia; Triglycerides

Indexed keywords

ANTIGEN; APOLIPOPROTEIN B48; C REACTIVE PROTEIN; CD11B ANTIGEN; CD66B ANTIGEN; CHOLESTEROL; CHYLOMICRON; CHYLOMICRON REMNANT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; AUTACOID; CEACAM8 PROTEIN, HUMAN; CELL ADHESION MOLECULE; FAT INTAKE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITGAM PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BODY FAT; CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; HUMAN; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; MIDDLE AGED; MONOCYTE; NEUTROPHIL; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ADMINISTRATION AND DOSAGE; BLOOD; CASE CONTROL STUDY; FAT INTAKE; LEUKOCYTE; METABOLISM; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD11B; APOLIPOPROTEIN B-48; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CHYLOMICRON REMNANTS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIETARY FATS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TRIGLYCERIDES;

EID: 84945546480     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.10.025     Document Type: Article

References (34)

1. Alipour A., van Oostrom A.J.H.H.M., Izraeljan A., Verseyden C., Collins J.M., Frayn K.N., et al. Leukocyte activation by triglyceride-rich lipoproteins. Arter. Thromb. Vasc. Biol. 2008, 28:792-797.
2. Gower R.M., Wu H., Foster G.A., Devaraj S., Jialal I., Ballantyne C.M., et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arter. Thromb. Vasc. Biol. 2011, 31:160-166.
3. Van Oostrom A.J.H.H.M., Rabelink T.J., Verseyden C., Sijmonsma T.P., Plokker H.W.M., De Jaegere P.P.T., et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis 2004, 177:175-182.
4. Libby P. Inflammation in atherosclerosis. Arter. Thromb. Vasc. Biol. 2012, 32:2045-2051.
5. Mazzone A., De Servi S., Mazzucchelli I., Fossati G., Gritti D., Canale C., et al. Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: a bridge between inflammation and coagulation. Eur. J. Clin. Invest. 1997, 27:648-652.
6. Mazzone A., De Servi S., Ricevuti G., Mazzucchelli I., Fossati G., Pasotti D., et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993, 88:358-363.
7. Murphy R.T., Foley J.B., Crean P., Walsh M.J. Reciprocal activation of leukocyte-endothelial adhesion molecules in acute coronary syndromes. Int. J. Cardiol. 2003, 90:247-252.
8. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
9. Mora S., Rifai N., Buring J.E., Ridker P.M. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118:993-1001.
10. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
11. Su J.W., Nzekwu M.-M.U., Castro Cabezas M., Redgrave T., Proctor S.D. Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur. J. Clin. Invest. 2009, 39:741-754.
12. Smith D., Watts G.F., Dane-Stewart C., Mamo J.C. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur. J. Clin. Invest. 1999, 29:204-209.
13. Cortner J.A., Coates P.M., Le N.A., Cryer D.R., Ragni M.C., Faulkner A., et al. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J. Lipid Res. 1987, 28:195-206.
14. Haberbosch W., Poli A., Augustin J. Characterization of human chylomicrons. Biochim. Biophys. Acta 1982, 713:398-409.
15. Proctor S.D., Mamo J.C.L. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arter. Thromb. Vasc. Biol. 2003, 23:1595-1600.
16. Botham K.M., Moore E.H., De Pascale C., Bejta F. The induction of macrophage foam cell formation by chylomicron remnants. Biochem. Soc. Trans. 2007, 35:454-458.
17. Proctor S.D., Vine D.F., Mamo J.C.L. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arter. Thromb. Vasc. Biol. 2004, 24:2162-2167.
18. Steiner G. Intermediate-density lipoproteins, diabetes and coronary artery disease. Diabetes Res. Clin. Pract. 1998, 40(Suppl. l):S29-S33.
19. Alipour A., Valdivielso P., Elte J.W.F., Janssen H.W., Rioja J., van der Meulen N., et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur. J. Clin. Invest. 2012, 42:702-708.
20. Valdivielso P., Ramírez-Bollero J., Pérez-López C. Peripheral artery disease, type 2 diabetes and postprandial lipidaemia: is there a link?. World J. Diabetes 2014, 5:577-585.
21. Mori K., Ishida T., Yasuda T., Monguchi T., Sasaki M., Kondo K., et al. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin. Chim. Acta 2013, 421:51-56.
22. Alipour A., Ribalta J., Njo T.L., Janssen H.W., Birnie E., van Miltenburg A.J.M., et al. Trans-vessel gradient of myeloperoxidase in coronary artery disease. Eur. J. Clin. Invest. 2013, 43:920-925.
23. Klop B., van de Geijn G.-J.M., Birnie E., Njo T.L., Janssen H.W., Jansen H.G., et al. Vitamin D3 mediated effects on postprandial leukocyte activation and arterial stiffness in men and women. Eur. J. Clin. Nutr. 2014, 68:635-637.
24. Kinoshita M., Kojima M., Matsushima T., Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin. Chim. Acta 2005, 351:115-120.
25. De Servi S., Mazzone A., Ricevuti G., Mazzucchelli I., Fossati G., Angoli L., et al. Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. Am. J. Cardiol. 1996, 78:564-568.
26. Engel D., Beckers L., Wijnands E., Seijkens T., Lievens D., Drechsler M., et al. Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response. FASEB J. 2011, 25:3838-3848.
27. Simons L.A., Dwyer T., Simons J., Bernstein L., Mock P., Poonia N.S., et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987, 65:181-189.
28. Bentley C., Hathaway N., Widdows J., Bejta F., De Pascale C., Avella M., et al. Influence of chylomicron remnants on human monocyte activation in vitro. Nutr. Metab. Cardiovasc Dis. 2011, 21:871-878.
29. Van Oostrom A.J.H.H.M., Plokker H.W.M., van Asbeck B.S., Rabelink T.J., van Kessel K.P.M., Jansen E.H.J.M., et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis 2006, 185:331-339.
30. Varela L.M., Ortega A., Bermudez B., Lopez S., Pacheco Y.M., Villar J., et al. A high-fat meal promotes lipid-load and apolipoprotein B-48 receptor transcriptional activity in circulating monocytes. Am. J. Clin. Nutr. 2011, 93:918-925.
31. Klop B., van der Pol P., van Bruggen R., Wang Y., de Vries M.A., van Santen S., et al. Differential complement activation pathways promote C3b deposition on native and acetylated LDL thereby inducing lipoprotein binding to the complement receptor 1. J. Biol. Chem. 2014, 289:35421-35430.
32. Blake G.J., Ridker P.M. Are statins anti-inflammatory?. Curr. Control Trials Cardiovasc Med. 2000, 1:161-165.
33. Antonopoulos A.S., Margaritis M., Lee R., Channon K., Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 2012, 18:1519-1530.
34. De Vries M.A., Alipour A., Klop B., van de Geijn G.-J.M., Janssen H.W., Njo T.L., et al. Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. Metabolism 2015, 64:213-217.